Sergio Capoccia

Sergio Capoccia

Auto-generated profile, based on publicly available information

Sergio Capoccia

Città della Salute e della Scienza

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
FGFederico Giacobbe
Federico Giacobbe
PMPierre Meynet
Pierre Meynet
MBMarco Balducci
Marco Balducci
SCSergio Capoccia
Sergio Capoccia
RCRino Andrea Cimino
Rino Andrea Cimino
GFGaetano Maria De Ferrari
Gaetano Maria De Ferrari
Coronary microvascular dysfunction (CMD) is a key driver of ischemia and prognosis across several non-ischemic cardiomyopathies. This review summarizes the main tools for diagnosing microvascular dysfunction and available evidence on CMD incidence and the prognostic role in patients with cardiomyopathies. In dilated cardiomyopathy, CMD is associated with reduced myocardial blood flow, greater fibrosis, adverse remodeling, and worse outcomes. In hypertrophic cardiomyopathy, CMD is highly prevalent and multifactorial (arteriolar remodeling, reduced capillary density, extravascular compression, diastolic dysfunction, and/or left ventricular (LV) outflow obstruction), correlating with fibrosis, heart failure, and arrhythmias/sudden death. In Takotsubo syndrome, CMD appears acute and reversible, with microvascular spasms as a predominant mechanism and plausible pathophysiologic basis of the event. In arrhythmogenic right ventricular cardiomyopathy, preliminary data show a blunted hyperemic response and autonomic abnormalities that may impair microvascular vasodilation. In infiltrative and storage diseases (amyloidosis and Anderson–Fabry disease), CMD is often early, preceding hypertrophy/fibrosis, and contributes to symptoms, contractile dysfunction, and adverse outcomes; in sarcoidosis, microvascular inflammation reduces coronary flow reserve (CFR) and is associated with events. Targeted therapies remain limited; optimization of risk factors and drugs that modulate endothelial/metabolic function (statins, angiotensin converting enzyme (ACE) inhibitors, vasodilating β-blockers, calcium channel blockers, sodium glucose cotransporter 2 (SGLT2) inhibitors) yielded variable signals; device-based and nonpharmacologic strategies are under investigation. In conclusion, integrating microcirculatory assessment improves risk stratification and may furnish future therapeutic targets across cardiomyopathies.

6 October 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
FGFederico Giacobbe
Federico Giacobbe
FBFrancesco Bruno
Francesco Bruno
MBMarco Brero
Marco Brero
PMPierre Meynet
Pierre Meynet
ASAndrea Solano
Andrea Solano
OFOvidio De Filippo
Ovidio De Filippo
Background: Despite continuous advancements in devices and techniques, transcatheter aortic valve implantation remains associated with complications impacting outcomes. In 2021, the Valve Academic Research Consortium (VARC) introduced the VARC‐3 criteria to better classify procedural complications. Methods: We conducted a systematic review and meta‐analysis of studies reporting transcatheter aortic valve implantation‐related complications using VARC‐3 definitions between 2021 and 2025. The primary end point was all‐cause mortality at latest follow‐up. Secondary end points included major VARC‐3 complications and predictors of adverse events. Results: A total of 57 studies with 73 588 patients were included. The cohort had a mean age of 81.7 years, 51.7% were women, and most had preserved ejection fraction (55.5%) and low‐to‐moderate surgical risk (Society of Thoracic Surgeons [STS] predicted risk of mortality [PROM] 4.1%). Technical and 30‐day device success rates were 95% and 90%, respectively; early safety rate at 30 days was 66%. At average 12 months follow‐up, all‐cause mortality was 10.2%. The most common complication was permanent pacemaker implantation (13%), followed by type 2 or greater bleeding (9.7%), acute kidney injury stage 3–4 (4.7%), major vascular events (4.3%), and stroke (3.0%). Moderate/severe paravalvular regurgitation and patient‐prosthesis mismatch occurred in 4% and 8%, respectively. Study‐level pooled predictor analyses showed that acute kidney injury, type 2 or greater bleeding, paravalvular regurgitation, non‐structural valve dysfunction, and higher STS score were associated with higher mortality, while eccentric/severe aortic valve calcification was associated with significant paravalvular regurgitation. Conclusions: Transcatheter aortic valve implantation shows high procedural success but non‐negligible complication rates under VARC‐3 criteria. acute kidney injury, type 2 or greater bleeding, NSVD, periprocedural stroke and myocardial infarction after transcatheter aortic valve implantation were associated with higher mortality.